107 related articles for article (PubMed ID: 29324332)
1. Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation.
Siudut J; Natorska J; Zabczyk M; Zajac D; Seweryn K; Rąpała-Kozik M; Undas A
Thromb Res; 2018 Mar; 163():12-18. PubMed ID: 29324332
[TBL] [Abstract][Full Text] [Related]
2. Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.
Żuk J; Snarska-Drygalska A; Malinowski KP; Papuga-Szela E; Natorska J; Undas A
J Thromb Thrombolysis; 2019 Feb; 47(2):248-254. PubMed ID: 30684190
[TBL] [Abstract][Full Text] [Related]
3. Prothrombotic fibrin clot properties are associated with post-discharge venous thromboembolism in acutely ill medical patients.
Wójcik M; Zaręba L; Undas A
Thromb Res; 2019 Oct; 182():141-149. PubMed ID: 31479942
[TBL] [Abstract][Full Text] [Related]
4. Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception.
Piróg M; Piwowarczyk S; Undas A
Dis Markers; 2019; 2019():4923535. PubMed ID: 31827635
[TBL] [Abstract][Full Text] [Related]
5. Fibrin clot properties in women heterozygous for factor V Leiden mutation: effects of oral contraceptives.
Krzek M; Ciesla-Dul M; Zabczyk M; Undas A
Thromb Res; 2012 Oct; 130(4):e216-21. PubMed ID: 22940058
[TBL] [Abstract][Full Text] [Related]
6. Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes.
Bryk AH; Konieczynska M; Rostoff P; Broniatowska E; Hohendorff J; Malecki MT; Undas A
Thromb Haemost; 2019 Feb; 119(2):213-222. PubMed ID: 30605917
[TBL] [Abstract][Full Text] [Related]
7. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
8. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism.
Fassel H; Chen H; Ruisi M; Kumar N; DeSancho M; Hajjar KA
Blood; 2021 Apr; 137(16):2221-2230. PubMed ID: 33512476
[TBL] [Abstract][Full Text] [Related]
10. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
[TBL] [Abstract][Full Text] [Related]
11. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives.
Undas A; Zawilska K; Ciesla-Dul M; Lehmann-Kopydłowska A; Skubiszak A; Ciepłuch K; Tracz W
Blood; 2009 Nov; 114(19):4272-8. PubMed ID: 19690336
[TBL] [Abstract][Full Text] [Related]
12. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
13. Unfavorably altered plasma clot properties in women with a HERDOO2 score equal to or greater than 2 and prediction of recurrent venous thromboembolism.
Mrozińska S; Cieślik J; Broniatowska E; Undas A
Pol Arch Intern Med; 2018 Oct; 128(10):572-579. PubMed ID: 30113019
[TBL] [Abstract][Full Text] [Related]
14. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure.
Undas A; Natorska J
Expert Rev Hematol; 2019 Aug; 12(8):597-607. PubMed ID: 31159611
[No Abstract] [Full Text] [Related]
15. Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.
Gajos G; Siniarski A; Natorska J; Ząbczyk M; Siudut J; Malinowski KP; Gołębiowska-Wiatrak R; Rostoff P; Undas A
Cardiovasc Diabetol; 2018 Nov; 17(1):146. PubMed ID: 30466424
[TBL] [Abstract][Full Text] [Related]
16. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
17. Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation.
Henderson SJ; Stafford AR; Leslie BA; Kim PY; Vaezzadeh N; Ni R; Fredenburgh JC; Weitz JI
Thromb Haemost; 2015 Jun; 113(6):1278-88. PubMed ID: 25789495
[TBL] [Abstract][Full Text] [Related]
18. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
19. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
Matusik PT; Matusik PS; Kornacewicz-Jach Z; Małecka B; Ząbek A; Undas A
Int J Cardiol; 2017 Sep; 243():244-250. PubMed ID: 28571619
[TBL] [Abstract][Full Text] [Related]
20. Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease.
Baker SR; Zabczyk M; Macrae FL; Duval C; Undas A; Ariëns RAS
J Thromb Haemost; 2019 Apr; 17(4):618-626. PubMed ID: 30725502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
